pharma · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu
News and analysis for Daihong Liu on NovaPharmaNews — regulatory, clinical, and market coverage.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 8
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Daihong Liu — regulatory, clinical, and market coverage.
News and analysis for Daihong Liu on NovaPharmaNews — regulatory, clinical, and market coverage.